

Attorney Docket No.: 930008-2210 (BOE0006US.NP)
Inventors: Runge and Lembcke
Serial No.: 10/593,657
Filing Date: April 16, 2007
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-36 (canceled).

Claim 37 (previously presented): A pharmaceutical formulation comprising crystalline and/or amorphous unmilled flutamide particles mixed with at least one surface-active substance, wherein the flutamide has been subjected to intensive mixing in a forced-action mixer with the at least one surface-active substance, wherein the size of 50% of the flutamide particles in the pharmaceutical formulation is greater than 26 μm .

Claim 38 (previously presented): The pharmaceutical formulation of claim 37, wherein said formulation further comprises at least one flow regulator and is in the form of a tablet.

Claim 39 (previously presented): The pharmaceutical formulation of claim 37, wherein said formulation is in the form of a filling for capsules.

Claim 40 (previously presented): The pharmaceutical formulation of claim 37, wherein said formulation is in the form of a dragée, effervescent tablet, suppository or granulate.

Attorney Docket No.: 930008-2210 (BOE0006US.NP)
Inventors: Runge and Lembcke
Serial No.: 10/593,657
Filing Date: April 16, 2007
Page 3

Claim 41 (previously presented): The pharmaceutical formulation of claim 37, wherein the flutamide has been subjected to recrystallisation.

Claims 42-45 (canceled).

Claim 46 (previously presented): The pharmaceutical formulation of claim 37, wherein the size of 90% of the flutamide particles (X90 value) is greater than 130 μm .

Claims 47-48 (canceled).

Claim 49 (previously presented): The pharmaceutical formulation of claim 37, wherein the flutamide particles have a specific surface area of less than $0.35 \text{ m}^2/\text{cm}^3$.

Claim 50 (previously presented): The pharmaceutical formulation of claim 37, wherein the flutamide is in the form of a free acid amide.

Claim 51 (previously presented): The pharmaceutical formulation of claim 37, wherein the at least one surface-active substance is selected from the group of an anionic compound, cationic compound and non-ionic surfactant.

Claim 52 (previously presented): The pharmaceutical formulation of claim 51 comprising sodium dodecylsulphate as surface-active substance.

Attorney Docket No.: 930008-2210 (BOE0006US.NP)
Inventors: Runge and Lembcke
Serial No.: 10/593,657
Filing Date: April 16, 2007
Page 4

Claim 53 (previously presented): The pharmaceutical formulation of claim 37 with a ratio by weight of flutamide:surface-active substance of from 5:1 to 30:1.

Claim 54 (previously presented): The pharmaceutical formulation of claim 53 with a ratio by weight of flutamide:surface-active substance of from 5:1 to 20:1.

Claim 55 (previously presented): The pharmaceutical formulation of claim 54 with a ratio by weight of flutamide:surface-active substance of from 10:1 to 15:1.

Claim 56 (previously presented): The pharmaceutical formulation of claim 37 in the form of an unshaped mixture or in the form of an article that has been subjected to shaping.

Claim 57 (previously presented): The pharmaceutical formulation of claim 56 with a content of from 50 to 2000 mg of flutamide.

Claim 58 (previously presented): The pharmaceutical formulation of claim 57 with a content of from 50 to 500 mg of flutamide.

Claim 59 (previously presented): The pharmaceutical formulation of claim 58 with a content of from 100 to 200 mg of flutamide.

Claim 60 (previously presented): The pharmaceutical formulation of claim 37, further comprising at least one

Attorney Docket No.: 930008-2210 (BOE0006US.NP)
Inventors: Runge and Lembcke
Serial No.: 10/593,657
Filing Date: April 16, 2007
Page 5

excipient selected from the group formed by inorganic fillers, organic fillers, binders, glidants, lubricants, flow regulators and disintegrants.

Claim 61 (previously presented): The pharmaceutical formulation of claim 37, wherein the formulation is mixed in a forced-action mixer for 1 to 180 minutes.

Claim 62 (previously presented): The pharmaceutical formulation of claim 61, wherein the formulation is mixed in a forced-action mixer for 3 to 60 minutes.